Sandoz affirms its generic anti-clotting drug will be approved

BASEL, Switzerland Sandoz is “confident” that it will win approval for a generic anti-clotting drug, according to published reports.

Reuters reported that Sandoz, the generics arm of Novartis, and partner Momenta Pharmaceuticals were hoping to gain approval of a generic version of Sanofi-Aventis’s Lovenox (enoxaparin), but that Sandoz CEO Jeff George was “cautiously optimistic.”

Teva and a partnership involving Watson Pharmaceuticals and Amphastar Pharmaceuticals are seeking approval for versions of the drug as well, according to Reuters. The drug is used to treat deep vein thrombosis.

Login or Register to post a comment.